Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Mr as Other of the company w.e.f. August 12, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs' board approved standalone and consolidated unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations stood at ₹37,531 lakhs, down from ₹52,962 lakhs in Q4 FY25 and ₹39,349 lakhs in Q1 FY25. Standalone net profit came in at ₹5,122 lakhs (EPS ₹5.65), compared to ₹4,714 lakhs (EPS ₹5.20) in the year-ago quarter. On a consolidated basis, revenue was ₹38,619 lakhs and net profit was ₹4,950 lakhs, including a ₹179.6 lakh loss from the new joint venture, Ganesh Polychem. The board also approved the re-appointment of Ms. Rupal Vora (DIN: 07096253) as Non-Executive Independent Director for a second term of 3 years from October 17, 2025, and recommended M/s Mehta & Mehta as Secretarial Auditors for 5 years. The stock option scheme was extended to subsidiary employees, subject to shareholder approval.
Revenue declined year-on-year, but the company posted a modest profit growth over Q1 FY25, with margin pressure visible. The board changes are routine governance items and unlikely to move the stock on their own; investors will likely focus more on the revenue slowdown and the loss contribution from the newly added joint venture.